EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
“We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience.
The appointment of
As we advance toward the clinical development of EGL-001, John’s expertise in business development in the field of oncology is instrumental for us to successfully execute on our strategic priorities.” said
“I am excited to join Egle Therapeutics to translate into the clinic the company's groundbreaking and unique science, whose innovative and versatile regulatory T-cell focused platform, a key component of the immune system, has a tremendous potential to change the treatment paradigm for the many patients with high unmet medical needs in oncology and auto-immunity” said Pejvack Motlagh, MD, MSc, CMO at Egle Therapeutics. As CMO, Pejvack will drive the clinical and medical strategy and development of our Company in the years to come.
“This is a transformational period for Egle Therapeutics as the company further strengthens its team and advances toward the clinic a series of highly novel candidates aimed at arming or disarming Treg function to achieve the desired therapeutic outcome. I look forward to collaborating with this talented Board and management team as we advance Egle’s compelling pipeline for patients with unmet need,” said
Pejvack Motlagh, MD,MSc, a seasoned clinical development executive who has previously held overall responsibility for candidate development from first in human through registrational studies, brings to Egle Therapeutics the appropriate expertise and successful drug development experience. As Chief Medical Officer, he will be responsible for advancing Egle’s pipeline towards the clinic and notably EGL-001 (a Treg-selective anti-CTLA4-IL-2m) in oncology and EGL-003 (a non-targeted IL-2 Treg engager) in auto-immune diseases. Prior to Egle Therapeutics,
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently developed in IND-enabling studies.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510313711/en/
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
Source: Egle Therapeutics SAS